Ardelyx Reports 12% Revenue Growth to $110.3 Million in Q3 2025

Ardelyx, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $110.3 million, a 12% increase from $98.2 million in the same period last year. The growth was primarily driven by a 15% rise in product sales, netting $105.5 million, compared to $92.1 million in Q3 2024. Notably, sales of IBSRELA, the company's treatment for irritable bowel syndrome with constipation (IBS-C), surged by 92% to $78.2 million, while sales of XPHOZAH, aimed at reducing serum phosphorus in chronic kidney disease patients, fell by 47% to $27.4 million due to the loss of Medicare Part D reimbursement starting January 1, 2025.

In terms of profitability, Ardelyx reported a net loss of $969,000 for the quarter, slightly higher than the loss of $809,000 in Q3 2024. For the nine months ending September 30, 2025, the net loss increased to $61.2 million from $43.8 million in the prior year. The company's accumulated deficit now stands at $946.5 million. Operating expenses rose significantly, with selling, general, and administrative costs increasing by 29% to $83.6 million, reflecting higher commercialization efforts for both IBSRELA and XPHOZAH.

Strategically, Ardelyx has made significant moves to bolster its product pipeline and financial position. The company announced the initiation of a development program for RDX10531, a next-generation NHE3 inhibitor, with plans to submit an Investigational New Drug (IND) application in 2026. Additionally, Ardelyx amended its 2022 Loan Agreement, allowing for an immediate draw of $50 million and the option to access an additional $100 million in senior secured term loans, which will support ongoing commercialization and development efforts.

Operationally, Ardelyx's cash and cash equivalents decreased to $42.7 million from $64.9 million at the end of 2024, while short-term investments increased to $200 million. The company reported a total of 242.9 million shares outstanding as of September 30, 2025. Ardelyx's management emphasized the importance of maintaining sufficient market acceptance for IBSRELA and XPHOZAH, particularly in light of the recent changes in reimbursement policies that could impact future revenue generation.

Looking ahead, Ardelyx remains focused on accelerating the growth of IBSRELA and executing its strategy for XPHOZAH, while also building a robust pipeline of new product candidates. The company acknowledges the challenges posed by market conditions and regulatory changes but is committed to navigating these complexities to achieve its long-term objectives.